Jared Gollob, Chief Medical Officer at Kymera Therapeutics, Inc. (KYMR), sold 93,914 shares at $91.46 ($8.3M) on 2025-12-08, disclosed to the SEC on 2025-12-08.
Scheduled sale ($8.3M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.37 | 13,759 | $1.2M | 14.5% |
| 2 | $87.37 | 13,759 | $1.2M | 14.5% |
| 3 | $88.02 | 18,357 | $1.6M | 19.4% |
| 4 | $88.02 | 18,357 | $1.6M | 19.4% |
| 5 | $89.43 | 3,929 | $351K | 4.2% |
| 6 | $89.43 | 3,929 |
| $351K |
| 4.2% |
| 7 | $90.12 | 8,562 | $772K | 9.3% |
| 8 | $90.12 | 8,562 | $772K | 9.3% |
| 9 | $91.46 | 3,300 | $302K | 3.6% |
| 10 | $92.19 | 1,400 | $129K | 1.6% |
| Total | $88.51 avg | 93,914 | $8.3M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $187K | — | Filing → |
| KYMR | SELL | 2025-03-03 | $317K | — | Filing → |
| KYMR | SELL | 2024-07-16 | $3.6M | — | Filing → |